首页> 外国专利> '' method for identifying a cancer patient who may benefit from antiagiogenic therapy, method for predicting a cancer patient's responsiveness to antiangiogenic therapy, use of an anti-vegf antibody to improve the effect of treating a cancer patient, method or use, useful kit for performing the method, use of a protein or usom kit useful for performing the method, use of a protein or oligonucleotide or polynecleotide matrix to determine the level of bfgf expression in a method and kit or use

'' method for identifying a cancer patient who may benefit from antiagiogenic therapy, method for predicting a cancer patient's responsiveness to antiangiogenic therapy, use of an anti-vegf antibody to improve the effect of treating a cancer patient, method or use, useful kit for performing the method, use of a protein or usom kit useful for performing the method, use of a protein or oligonucleotide or polynecleotide matrix to determine the level of bfgf expression in a method and kit or use

机译：''识别可能受益于抗血管生成治疗的癌症患者的方法，预测癌症患者对抗血管生成治疗的反应的方法，使用抗Vegf抗体改善治疗癌症患者的效果的方法，用途或用途，适用的试剂盒执行该方法，使用可用于执行该方法的蛋白质或usom试剂盒，使用蛋白质或寡核苷酸或多核苷酸基质来确定方法和试剂盒或用途中bfgf表达的水平

页面导航

摘要
著录项
相似文献

摘要

abstract not avaible

机译：摘要不可用

著录项

公开/公告号BR112012005670A2

专利类型
公开/公告日2017-01-10

原文格式PDF
申请/专利权人 F. HOFFMANN LA ROCHE AG;
展开▼

申请/专利号BR20121105670
发明设计人 PAUL DELMAR;SANNE LYSBET DE HAAS;STEFAN SCHERER;
展开▼

申请日2010-09-16
分类号C12Q1/68;
国家 BR
入库时间 2022-08-21 13:40:55

相似文献

专利
外文文献